To evaluate the association, the study authors utilized healthcare databases from Ontario, Canada to identify adults 66 years of age and older with no history of AF who filled at least 1 prescription for levothyroxine.
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
Findings showed the study met the primary end point of reduction in cardiovascular death or heart failure events.
The objective of the statement was to review and discuss medications that may cause or exacerbate arrhythmias.
The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.
Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.
Patients with heart failure receiving flu, pneumonia vaccinations have lower in-hospital mortality
Inadvertent administration may result in serious adverse events.
In an observational study, furosemide doses of 250 to 500 mg and spironolactone doses of 50 to 100 mg were independently associated with approximately 14% and 20% increased odds of hyponatremia, respectively.
Preoperative, intraoperative, postoperative strategies can help prevent perioperative stroke
